Can ABCF2 protein expression predict the prognosis of uterine cancer?

S. Nishimura, H. Tsuda, Y. Miyagi, A. Hirasawa, A. Suzuki, F. Kataoka, H. Nomura, T. Chiyoda, K. Banno, T. Fujii, N. Susumu, D. Aoki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr)=1.437), old age (rr=1.550) and advanced stage (rr=2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

Original languageEnglish
Pages (from-to)1651-1655
Number of pages5
JournalBritish Journal of Cancer
Volume99
Issue number10
DOIs
Publication statusPublished - 04-11-2008

Fingerprint

Uterine Neoplasms
Adenosine Triphosphate
Endometrial Neoplasms
Proteins
Uterine Cervical Neoplasms
Odds Ratio
Estrogen Receptors
Neoplasms
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nishimura, S., Tsuda, H., Miyagi, Y., Hirasawa, A., Suzuki, A., Kataoka, F., ... Aoki, D. (2008). Can ABCF2 protein expression predict the prognosis of uterine cancer? British Journal of Cancer, 99(10), 1651-1655. https://doi.org/10.1038/sj.bjc.6604734
Nishimura, S. ; Tsuda, H. ; Miyagi, Y. ; Hirasawa, A. ; Suzuki, A. ; Kataoka, F. ; Nomura, H. ; Chiyoda, T. ; Banno, K. ; Fujii, T. ; Susumu, N. ; Aoki, D. / Can ABCF2 protein expression predict the prognosis of uterine cancer?. In: British Journal of Cancer. 2008 ; Vol. 99, No. 10. pp. 1651-1655.
@article{7229207e39634612909e8f93dd87b124,
title = "Can ABCF2 protein expression predict the prognosis of uterine cancer?",
abstract = "Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8{\%}) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr)=1.437), old age (rr=1.550) and advanced stage (rr=2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9{\%}) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.",
author = "S. Nishimura and H. Tsuda and Y. Miyagi and A. Hirasawa and A. Suzuki and F. Kataoka and H. Nomura and T. Chiyoda and K. Banno and T. Fujii and N. Susumu and D. Aoki",
year = "2008",
month = "11",
day = "4",
doi = "10.1038/sj.bjc.6604734",
language = "English",
volume = "99",
pages = "1651--1655",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

Nishimura, S, Tsuda, H, Miyagi, Y, Hirasawa, A, Suzuki, A, Kataoka, F, Nomura, H, Chiyoda, T, Banno, K, Fujii, T, Susumu, N & Aoki, D 2008, 'Can ABCF2 protein expression predict the prognosis of uterine cancer?', British Journal of Cancer, vol. 99, no. 10, pp. 1651-1655. https://doi.org/10.1038/sj.bjc.6604734

Can ABCF2 protein expression predict the prognosis of uterine cancer? / Nishimura, S.; Tsuda, H.; Miyagi, Y.; Hirasawa, A.; Suzuki, A.; Kataoka, F.; Nomura, H.; Chiyoda, T.; Banno, K.; Fujii, T.; Susumu, N.; Aoki, D.

In: British Journal of Cancer, Vol. 99, No. 10, 04.11.2008, p. 1651-1655.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can ABCF2 protein expression predict the prognosis of uterine cancer?

AU - Nishimura, S.

AU - Tsuda, H.

AU - Miyagi, Y.

AU - Hirasawa, A.

AU - Suzuki, A.

AU - Kataoka, F.

AU - Nomura, H.

AU - Chiyoda, T.

AU - Banno, K.

AU - Fujii, T.

AU - Susumu, N.

AU - Aoki, D.

PY - 2008/11/4

Y1 - 2008/11/4

N2 - Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr)=1.437), old age (rr=1.550) and advanced stage (rr=2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

AB - Uterine cervical and endometrial cancers are common malignant solid neoplasms for which there are no useful prognostic markers. In this study, we evaluate the relationship between ATP-binding cassette superfamily F2 (ABCF2) expression and clinical factors including clinical stage, histologic type, grade and prognosis in uterine cervical and endometrial cancer. Two hundred and sixty seven cervical and 103 endometrial cancers were studied. ATP-binding cassette superfamily F2 cytoplasmic expression was detected by immunohistochemical staining and scored as positive or negative. Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (P=0.0069). Statistically significant prognostic factors for survival were ABCF2 positivity (risk ratio (rr)=1.437), old age (rr=1.550) and advanced stage (rr=2.577). ATP-binding cassette superfamily F2 positivity was an independent prognostic factor by multivariate proportional hazard test (P=0.0002). Among endometrial cancer cases, 72 (69.9%) were cytoplasmic ABCF2 positive. However, there was no significant relationship between ABCF2 expression and age, clinical stage, histologic type, histologic grade, oestrogen receptor status or prognosis. ATP-binding cassette superfamily F2 expression may be a useful prognostic marker in cervical but not endometrial cancer. The role of ABCF2 protein may differ depending on the type of cancer.

UR - http://www.scopus.com/inward/record.url?scp=55949128810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949128810&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604734

DO - 10.1038/sj.bjc.6604734

M3 - Article

C2 - 19002184

AN - SCOPUS:55949128810

VL - 99

SP - 1651

EP - 1655

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -

Nishimura S, Tsuda H, Miyagi Y, Hirasawa A, Suzuki A, Kataoka F et al. Can ABCF2 protein expression predict the prognosis of uterine cancer? British Journal of Cancer. 2008 Nov 4;99(10):1651-1655. https://doi.org/10.1038/sj.bjc.6604734